NCT02227108 - Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

B-Cell Pediatric ALL

Interventions

DRUG

Moxetumomab Pasudotox

Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.

Trial Locations (21)

Unknown

Research Site, Phoenix

Research Site, Los Angeles

Research Site, Chicago

Research Site, Bethesda

Research Site, Kansas City

Research Site, New York

Research Site, Durham

Research Site, Columbus

Research Site, Philadelphia

Research Site, Seattle

Research Site, Parkville

Research Site, Westmead

Research Site, Edmonton

Research Site, Lyon

Research Site, Paris

Research Site, Vandœuvre-lès-Nancy

Research Site, Rome

Research Site, Rotterdam

Research Site, Barcelona

Research Site, Madrid

Research Site, Bristol